Webinar: PackGene’s Next-Generation Dual-Plasmid System for AAV Manufacturing
Abstract
Join us for a webinar on PackGene’s Next-Generation Dual-Plasmid System for AAV Manufacturing.
Gene therapy is advancing quickly, driven by the safe and effective delivery of adeno-associated virus (AAV) vectors. Yet manufacturing remains a key challenge, as the demand for high-dose therapies continues to exceed current production capabilities.
For over two decades, the traditional triple-plasmid system has been the industry standard. While reliable, this method is challenged by high costs, complexity, and a persistent risk of producing replication-competent AAV (rcAAV), a critical safety concern.
In this webinar, we will unveil PackGene's innovative TP011 dual-plasmid system, a next-generation solution engineered to overcome these challenges. Our proprietary non-coding regulatory element and systematic process optimization have resulted in a platform that not only enhances safety by minimizing rcAAV risk but also delivers significantly higher viral yields.
Learn how PackGene's end-to-end manufacturing platform provides a cost-effective, scalable, and robust solution for gene therapy, helping to meet growing pipeline demands and accelerate the development of life-changing medicines.
Time
Sept 30, 2025, Tue, 2:00-3:00 pm EDT, 11:00am -12:00pm PDT
Speaker:
-
Read moreName: Amos Gutnick, Ph.D.
Institute/Company: PackGene Biotech
Title: Business Development Manager
Related Service
-
AAV Packaging Services
- Fast turnaround with high-quality, low empty capsids
- 70+ serotypes, 40+ QC assays, expert design support
- 50,000+ AAVs delivered, scalable to GMP grade
-
AAV Packaging – Research Grade
- As fast as 12 days from miniprep to virus
- High purity, low endotoxin and empty capsids
- 70+ serotypes and 50,000+ projects with expert support
-
AAV Packaging – NHP Grade
- Endotoxin-free with strict contamination control
- ddPCR-quantified titer and confirmed genome integrity
- Enhanced safety and efficacy with consistent results
